NEWS

A typical non-profit structure includes a board of directors, who oversee the organization at a high level and ensure the mission is being pursued, and staff, who execute the vision of the board. In between these levels there is the possibility for another layer: committees. Committees for non-profits are often comprised of people who are… Read More »WHAT ARE MPN RESEARCH FOUNDATION COMMITTEES?

MPN Research Foundation and The Leukemia & Lymphoma Society Partner to Spur Innovation in Fibrosis Research  In January 2012 the Myeloproliferative Neoplasm (MPN) Research Foundation and The Leukemia & Lymphoma Society (LLS) will jointly issue a Request for Proposals (RFP) seeking innovative approaches to reversing fibrosis in patients with myelofibrosis (MF).  Applicants for this concept… Read More »NEW GRANT OPPORTUNITY FOR MYELOFIBROSIS

April 2011 The Belgian Journal of Hematology recently published their review of the state of JAK Inhibitors. Since its discovery in 2005 several companies have been working on creating a JAK Inhibitor for treatment of the myeloproliferative neoplasms. Click here to read the full article (PDF) Current trials for polycythemia vera, essential thrombocythemia and myelofibrosis… Read More »EUROPEAN JOURNAL OFFERS REVIEW OF CURRENT JAK INHIBITORS

March 2011 The patients who run the MPD Foundation are impatient to see results from the medical research they fund. That’s understandable: their rare blood diseases – essential thrombocythemia, polycythemia vera and myelofibrosis, collectively called myeloproliferative neoplasms – are progressive, incurable and generally not well managed by existing medicines. So, in its latest round of… Read More »PATIENTS PUSH RESEARCHERS TO SHARE DATA

February 2011 The MPN Research Foundation (formerly MPD Foundation) is pleased to announce the recipients of its Established Investigator and New Investigator grants for 2011. These awards follow an extensive proposal review process conducted by the MPN Research Foundation’s Scientific Advisory Board as well as additional MPN experts who gave generously of their time and… Read More »2011 MPN RESEARCH FOUNDATION

January 2011 Geron Corporation has enrolled their first person in a Phase 2 clinical trial to test their drug (GRN163L) in patients with essential thrombocythemia. These drugs are aiming to target the leukemic stem cell, which Geron believes will “impact the biology of the disease”. This Phase 2 trial is testing the safety and efficacy… Read More »GERON ENROLLS FIRST PATIENT IN DRUG STUDY FOR ESSENTIAL THROMBOCYTHEMIA

December 2010 Incyte Corp. is currently working on phase II clinical trials for their JAK Inhibitor INCB18424. These trials are testing safety and efficacy of this drug, meant to relieve constitutional symptoms in ET and PV patients. Results were reported at the American Society of Hematology’s annual meeting. Click here for more information

December 2010 Data from SBio’s ongoing clinical trial for their JAK2 Inhibitor SB1518 was reported at the recent annual meeting of the American Society of Hematology. Dr. Srdan Verstovsek reported that thus far 57% of patients enrolled had experience reduction in spleen as well as reduction in constitutional symptoms of myelofibrosis. The drug was reported… Read More »SBIO DRUG SHOWS PROMISE FOR SYMPTOM AND SPLEEN REDUCTION FOR MYELOFIBROSIS PATIENTS

November 2010By Ann Brazeau The MPD Foundation hosted a patient educational symposium in San Diego on October 25, 2010 at the UCSD Moores Cancer Center in La Jolla. Each speaker commended the attendees for taking an active role in learning about their rare blood cancer and for supporting research and awareness efforts to ensure better… Read More »MPN RESEARCH FOUNDATION’S SAN DIEGO SYMPOSIUM BRINGS THE EXPERTS TO THE PATIENTS

October 2010 Click here to read about a New Jersey MF patient and her struggle with MF.